PMGC
ELAB | NASDAQ
$1.66
+$0.08 (+5.06%)
At close: Nov 16, 2026, 4:00 PM ET
$1.56
-$0.10 (-6.05%)
After-hours:
Nov 16, 2026, 7:58 PM ET
PMGC Company Profile
Company profile explainedCompany Profile
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Key Executives
| Name | Position |
|---|---|
| Graydon Bensler | Chief Executive Officer, Chief Financial Officer, Secretary & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 8-K | Current Report |
| Oct 22, 2026 | SC 13D/A | [Amend] Filing |
| Oct 22, 2026 | 4 | Filing |
| Sep 29, 2026 | SC 13D | Filing |
| Sep 18, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 8-K | Current Report |
| Aug 27, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Jul 09, 2026 | 8-K | Current Report |
| Jul 07, 2026 | 8-K | Current Report |
PMGC
| Country | United States |
| IPO Date | Nov 21, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Graydon Bensler |
Contact Details
120 Newport Center Drive Newport Beach,
California 92660 United States
Stock Details
| Ticker Symbol | ELAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840563 |
| CUSIP Number | 73017P607 |
| ISIN Number | US73017P6079 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ELAB